Skip to main content
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in

Search

  • Advanced search
Cancer Research
Cancer Research

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
Tumor Biology

Abstract #LB-63: Investigating the Requirement of NF-\#954;B Pathway Activation in MYC-Induced Liver Cancer

David Bellovin, Qiwei Yang and Dean Felsher
David Bellovin
Stanford University School of Medicine, Stanford, CA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Qiwei Yang
Stanford University School of Medicine, Stanford, CA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dean Felsher
Stanford University School of Medicine, Stanford, CA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published May 2009
  • Article
  • Info & Metrics
Loading
AACR Annual Meeting-- Apr 18-22, 2009; Denver, CO

Abstract

Liver cancer is one of the most lethal forms of cancer with a 5-year survival rate of less than 5%. Hence, it is critical to identify pathways that may be essential for the genesis of liver cancer and can thus be targeted for therapeutic intervention. One such potential target is the nuclear factor-kappa B (NF-\#954;B) pathway. Recently, our laboratory developed a conditional transgenic murine model of MYC-induced liver cancer that is dependent upon the expression of this oncogene and regresses following its inactivation. In order to examine whether NF-\#954;B activation is essential for MYC-induced liver cancer, we established a transgenic system in which MYC can be activated in hepatocytes concomitantly with a mutant form of I\#954;B, thereby inhibiting the NF-\#954;B pathway. Excitingly, this approach has revealed that suppression of NF-\#954;B activation can significantly inhibit MYC-induced hepatocellular carcinoma in adult animals. Indeed, most animals remain tumor free even up to 8 months after oncogene activation compared to mortality in 100% of animals expressing only MYC within 6 months. Moreover, in the hosts that do develop liver tumors, there is evidence for activation of the NF-\#954;B, indicating a necessity for this pathway. Importantly, suppression of NF-\#954;B activation is not only similarly able to inhibit MYC-induced tumor formation in neonatal hosts, but animals that develop HCC in this context demonstrate a strikingly different tumor phenotype. Finally, analysis of tumor samples in which MYC has been inactivated reveals that there is a concomitant decrease in expression of NF-\#954;B target genes, suggesting a direct role of MYC in activation of NF-\#954;B in hepatocytes. Together, these data demonstrate that inhibition of the NF-\#954;B pathway is sufficient to abrogate MYC\#8217;s ability to induce tumorigenesis in the liver and thereby establish NF-\#954;B activation as an attractive therapeutic target for liver cancer.

Citation Information: In: Proc Am Assoc Cancer Res; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR; 2009. Abstract nr LB-63.

Footnotes

  • 100th AACR Annual Meeting-- Apr 18-22, 2009; Denver, CO

  • American Association for Cancer Research
Back to top
Cancer Research: 69 (9 Supplement)
May 2009
Volume 69, Issue 9 Supplement
  • Table of Contents
  • Index by Author

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Abstract #LB-63: Investigating the Requirement of NF-\#954;B Pathway Activation in MYC-Induced Liver Cancer
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
Citation Tools
Abstract #LB-63: Investigating the Requirement of NF-\#954;B Pathway Activation in MYC-Induced Liver Cancer
David Bellovin, Qiwei Yang and Dean Felsher
Cancer Res May 1 2009 (69) (9 Supplement) LB-63;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Abstract #LB-63: Investigating the Requirement of NF-\#954;B Pathway Activation in MYC-Induced Liver Cancer
David Bellovin, Qiwei Yang and Dean Felsher
Cancer Res May 1 2009 (69) (9 Supplement) LB-63;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Tumor Biology

  • Abstract SY34-04: Do we need to know what pO2 hypoxia is
  • Abstract SY28-04: Rational incorporation of novel agents into multimodality treatment of glioma and neuroblastoma
  • Abstract SY28-02: Connections in the BRCA1-BRCA2 pathway of homologous recombination: Implications for breast cancer development and treatment
Show more 3

Mouse Models of Human Cancer -- Poster Presentations - Late-Breaking Abstracts

  • Abstract #LB-56: Suppression of anti-tumor immunity by E2F3
  • Abstract #LB-60: PTEN deficient mouse model for lymphoproliferative disease and lymphomagenesis
  • Abstract #LB-57: Development of lung adenocarcinoma in mice overexpressing calreticulin under control of the Tie-2 promoter
Show more 3
  • Home
  • Alerts
  • Feedback
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2018 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement